Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma

BACKGROUND: Targeting human epidermal growth factor receptor 2 (HER2) with trastuzumab in metastatic esophagogastric adenocarcinoma (EGA) improves survival. The impact of HER2 inhibition in combination with chemoradiotherapy (CRT) in early stage EGA is under investigation. This study analyzed the pa...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Gastrointest Oncol
Egile Nagusiak: Chan, Ellie, Duckworth, Lizette Vila, Alkhasawneh, Ahmad, Toro, Tania Zuluaga, Lu, Xiaomin, Ben-David, Kfir, Hughes, Steven J., Rossidis, Georgios, Zlotecki, Robert, Lightsey, Judith, Daily, Karen C., Dang, Long, Allegra, Carmen J., King, Brent, George, Thomas J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AME Publishing Company 2016
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4783750/
https://ncbi.nlm.nih.gov/pubmed/27034783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2015.071
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak